pyrazinamide has been researched along with Body Weight in 25 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the blood levels, pharma-cokinetics and pharmacodynamic indices of pyrazinamide (PZA) in children suffering from tuberculosis, at doses administered under the weight band system of Revised National Tuberculosis Control Program of India (RNTCP) of India." | 9.16 | Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program. ( Gupta, P; Khanna, A; Roy, V; Sahni, P; Sethi, GR, 2012) |
| "In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 7.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
| "To evaluate the blood levels, pharma-cokinetics and pharmacodynamic indices of pyrazinamide (PZA) in children suffering from tuberculosis, at doses administered under the weight band system of Revised National Tuberculosis Control Program of India (RNTCP) of India." | 5.16 | Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program. ( Gupta, P; Khanna, A; Roy, V; Sahni, P; Sethi, GR, 2012) |
| " We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child." | 3.91 | Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. ( Dodd, PJ; Dooley, KE; Garcia-Prats, AJ; Hesseling, AC; McKenna, L; Radtke, KK; Savic, RM, 2019) |
| " The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children." | 3.81 | The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. ( Gie, RP; Graham, SM; Grzemska, M, 2015) |
| " The objectives of this investigation were to evaluate the impact of body weight on the overall systemic exposure to pyrazinamide (PZA) and to assess whether the use of one fixed dose, without adjustment according to weight, would ensure target exposure and safety requirements across the overall patient population." | 3.78 | Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. ( Della Pasqua, O; Sahota, T, 2012) |
| "In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients." | 3.70 | Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999) |
| "An analysis carried out on the dosage schemes adopted in several controlled clinical trials in tuberculosis has indicated that preestablishing the daily doses of isoniazid, rifampicin, and pyrazinamide in the initial intensive phase results in large deviations of the doses administered from those considered appropriate in mg/kg body weight." | 3.67 | Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase. ( Acocella, G; Angel, JH, 1986) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "5% of tuberculosis (TB) cases reported in 2003 in Taipei City had no recorded pre-treatment body weight and that among those who had, inconsistent dosing of anti-TB drugs was frequent." | 1.38 | Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan. ( Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012) |
| " Intensive pharmacokinetic sampling was performed for rifampin, pyrazinamide, and ethambutol at steady state." | 1.36 | Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. ( Aarnoutse, RE; Adhiarta, IG; Alisjahbana, B; Kariadi, SH; Nijland, HM; Ruslami, R; van Crevel, R, 2010) |
| "Poor bioavailability of rifampicin (R) in combination with other anti-tuberculosis drugs such as isoniazid (H), pyrazinamide (Z), and ethambutol (E) is a subject of much concern for the last few decades." | 1.32 | Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ( Chandrasekaran, V; Gurumurthy, P; Immanuel, C; Prabhakar, R; Ramachandran, G; Venkatesan, P, 2003) |
| "All 44 non-private hospitals in Malawi treating pulmonary tuberculosis (PTB) patients with an oral regimen (0." | 1.32 | Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi. ( Gausi, F; Harries, AD; Salaniponi, FM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruslami, R | 1 |
| Nijland, HM | 1 |
| Adhiarta, IG | 1 |
| Kariadi, SH | 1 |
| Alisjahbana, B | 1 |
| Aarnoutse, RE | 1 |
| van Crevel, R | 1 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 2 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Bhavani, PK | 1 |
| Gangadevi, NP | 1 |
| Swaminathan, S | 1 |
| Gupta, A | 1 |
| Dooley, KE | 2 |
| Savic, RM | 2 |
| Radtke, KK | 1 |
| Dodd, PJ | 1 |
| Garcia-Prats, AJ | 1 |
| McKenna, L | 1 |
| Hesseling, AC | 1 |
| Piubello, A | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Van Deun, A | 1 |
| Lodha, R | 1 |
| Mukherjee, A | 1 |
| Singh, V | 1 |
| Singh, S | 1 |
| Friis, H | 1 |
| Faurholt-Jepsen, D | 1 |
| Bhatnagar, S | 1 |
| Saini, S | 1 |
| Kabra, SK | 1 |
| Grewal, HM | 1 |
| Graham, SM | 1 |
| Grzemska, M | 1 |
| Gie, RP | 1 |
| Adhvaryu, MR | 1 |
| Reddy, N | 1 |
| Vakharia, BC | 1 |
| Roy, V | 1 |
| Sahni, P | 1 |
| Gupta, P | 1 |
| Sethi, GR | 1 |
| Khanna, A | 1 |
| Sahota, T | 1 |
| Della Pasqua, O | 1 |
| Chiang, CY | 1 |
| Yu, MC | 1 |
| Shih, HC | 1 |
| Yen, MY | 1 |
| Hsu, YL | 1 |
| Yang, SL | 1 |
| Lin, TP | 1 |
| Bai, KJ | 1 |
| Immanuel, C | 1 |
| Gurumurthy, P | 1 |
| Venkatesan, P | 1 |
| Chandrasekaran, V | 1 |
| Prabhakar, R | 1 |
| Harries, AD | 1 |
| Gausi, F | 1 |
| Salaniponi, FM | 1 |
| Zítková, L | 2 |
| Stastná, J | 2 |
| Tousek, J | 1 |
| Viklický, J | 1 |
| Anglaret, X | 1 |
| Saba, J | 1 |
| Perronne, C | 1 |
| Lacassin, F | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Durrheim, DN | 1 |
| Belt, EL | 1 |
| Shibata, K | 1 |
| Ishikawa, A | 1 |
| Kondo, T | 1 |
| Cakir, B | 1 |
| Yönem, A | 1 |
| Güler, S | 1 |
| Odabaşi, E | 1 |
| Demirbaş, B | 1 |
| Gürsoy, G | 1 |
| Aral, Y | 1 |
| Reese, OG | 1 |
| Steele, TH | 1 |
| Acocella, G | 1 |
| Angel, JH | 1 |
| Suzuki, T | 1 |
| Gomi, J | 1 |
| Aoyagi, T | 1 |
| Evans, DA | 1 |
| Celikovská, G | 1 |
| Kürti, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients[NCT00801606] | Phase 3 | 403 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for pyrazinamide and Body Weight
| Article | Year |
|---|---|
Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.
Topics: Adolescent; Antitubercular Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschoo | 2014 |
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju | 2008 |
Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program.
Topics: Antitubercular Agents; Body Weight; Child; Child, Preschool; Communicable Disease Control; Humans; I | 2012 |
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched | 1996 |
A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months.
Topics: Antibody Formation; Body Weight; Clinical Trials as Topic; Cycloserine; Drug Combinations; Drug Resi | 1975 |
20 other studies available for pyrazinamide and Body Weight
| Article | Year |
|---|---|
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
Topics: Adult; Antitubercular Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administra | 2010 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.
Topics: Algorithms; Antitubercular Agents; Body Weight; Child Nutrition Disorders; Child, Preschool; Drug Ad | 2019 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Topics: Antitubercular Agents; Body Weight; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 2015 |
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
Topics: Antitubercular Agents; Area Under Curve; Body Weight; Drug Dosage Calculations; Ethnicity; Female; H | 2012 |
Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations | 2012 |
Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Area Under Curve; Body Weight; Ethambutol; Humans; I | 2003 |
Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Weight; Commun | 2004 |
Toxicity of morphazinamide compared with pyrazinamide.
Topics: Animals; Blood Chemical Analysis; Body Weight; Eating; Liver; Male; Pyrazinamide; Pyrazines; Rats; R | 1983 |
Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Body Weight; Drug Administratio | 1994 |
Tuberculosis control programme guidelines--treatment regimens.
Topics: Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 1996 |
Effects of dietary pyrazinamide on the metabolism of tryptophan to niacin in streptozotocin-diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glycosuria; Male; Niacin; Poly | 1997 |
Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Mass Index; Body Weight; Drug Therap | 1999 |
Renal transport of urate during diuretic-induced hypouricemia.
Topics: Adult; Body Weight; Calcium; Diuretics; Glomerular Filtration Rate; Glycolates; Hematocrit; Humans; | 1976 |
Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.
Topics: Antitubercular Agents; Body Weight; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifa | 1986 |
[Experimental studies on intermittent use of rifampicin alone or combined with other secondary antituberculous drugs].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antitubercular Agents; Body Weight; Ethambutol | 1971 |
Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
Topics: Adult; Body Weight; Drug Therapy, Combination; Ethambutol; Exanthema; Female; Fever; Follow-Up Studi | 1973 |
Genetic variations in the acetylation of isoniazid and other drugs.
Topics: Adult; Aminobenzoates; Aminosalicylic Acids; Asian People; Black People; Body Weight; Depression; Fe | 1968 |
[Liver damage after administration of pyrazinamide in animal experiments. I. Changes in body weight of rats under effect of pyrazinamide].
Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Depression, Chemical; Feeding Behavior | 1970 |